'The transformation continuum’
Following the acquisition of RUA Medical Devices Limited by AorTech International plc, the combination has released their first set of final results under the company’s new banner of ‘RUA Life Sciences plc’. The name change has not been the only transformation as RUA is now a fully integrated medical device company with FY 2020 revenues of £489k, a cash balance as at 7 July 2020 of £1.5m, plus much more to come in product development news in FY 2021.FY 2020 Results
Licence fees and royalties from the legacy business, now known as RUA Biomaterials, increased 5.6% to £489k (vs. £463k for the year to March 2019) – not significantly different to our £490k estimate. Administration expenses, which included R&D for the products in development in the RUA Vascular and RUA Structural Heart divisions as well as patent maintenance costs in RUA Biomaterials, increased 36.6% to £1,123k (vs. £822k in FY 2019) as these products progressed through animal implantation towards clinical trials and regulatory approval.
The R&D expenditure increased the FY 2020 operating loss to £941k compared to £638k in FY 2019. Yet the addition of £81k in R&D tax rebate and £44k in finance income (£0 and £29k in FY 2019) resulted in the net loss only increasing by 34.0% or £816k in FY 2020, compared to £609k in FY 2019. RUA Life Sciences’ cash balance was £1,976k at the end of FY 2020 (compared to £2,412k at end FY 2019) and £1,507k on 7 July 2020 after the costs of the RUA Medical acquisition. We forecast RUA’s cash runway will extend into 2022 and would anticipate a fund-raising based on positive product development news before then.
Many moving parts and product developments
RUA Medical also brings significant customer revenues to RUA Life Sciences in addition to the capabilities, manufacturing, testing and design facilities. We now forecast total revenues increasing to £1,933k in FY 2021, even taking account of the shortfall brought about by fewer elective surgical procedures resulting from the global coronavirus pandemic. Adding to this income will be the PERF grant and increasing R&D tax rebates.
Valuation unchanged by grant funding
We have updated our financials and forecasts, but only change our valuation to reflect RUA’s cash balance. We value RUA Life Sciences at £99.3m or 676p per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.